The studys results provide insights into some known and previously unrecognized benefits and risks of GLP-1RA that may be useful to inform clinical care and guide research agendas. Al-Aly emphasized that his study also highlighted potential downsides to the medications, including an increased risk of gastrointestinal problems such as nausea, vomiting, diarrhea, and in rare cases paralysis of the stomach
As research progresses, clearer guidelines can be developed to manage these interactions effectively, ensuring that patients receive the most beneficial and harmonized treatment approach
As a class, the DPP-4 inhibitors are weight neutral, causing neither weight gain nor weight loss
Blood pressure and heart rate should be monitored at each visit, particularly during dose titration phases
There will be a bit of soreness, too
In a more recent study by Choung et al., fimasartan ( 16 ) (Kim et al., 2012), an AT1 receptor antagonist approved in South Korea, was used as a starting point for optimization of PPAR modulatory activity ( 17 reached higher activation efficacy compared to the lead structure and exhibited antihypertensive activity in vivo
)
